炎症
Online ISSN : 1884-4006
Print ISSN : 0389-4290
ISSN-L : 0389-4290
慢性関節リウマチの治療における免疫調節剤CCAの適用と選択順位
小倉 博人
著者情報
ジャーナル フリー

1988 年 8 巻 2 号 p. 157-165

詳細
抄録
Lobenzarit exerts various kind of modulating effect on lymphocyte and significantly therapeutic activity in rheumatoid arthritis. However it is not known yet whether lobenzarit affects some paticular mechanism on pathogenesis of rheumatoid arthritis by correcting some abnormality. A long term clinical study was performed to assess the effectiveness of lobenzarit taken over extended periods by patients with rheumatoid arthritis. Consequently, it was shown that lobenzarit has favorable characteristics as a second line drug, but usually affords greater clinical benefit when used as a first line drug in the early stage of rheumatoid arthritis.
著者関連情報
© 日本炎症・再生医学会
前の記事 次の記事
feedback
Top